- Home
- TERN vs SLN Comparison
TERN vs SLN Comparison
Compare TERN & SLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TERN
- SLN
- Stock Information
- Founded
- TERN 2017
- SLN 1994
- Country
- TERN United States
- SLN United Kingdom
- Employees
- TERN N/A
- SLN N/A
- Industry
- TERN Biotechnology: Pharmaceutical Preparations
- SLN Biotechnology: Pharmaceutical Preparations
- Sector
- TERN Health Care
- SLN Health Care
- Exchange
- TERN Nasdaq
- SLN Nasdaq
- Market Cap
- TERN 321.4M
- SLN 281.0M
- IPO Year
- TERN 2021
- SLN N/A
- Fundamental
- Price
- TERN $3.80
- SLN $5.92
- Analyst Decision
- TERN Buy
- SLN Buy
- Analyst Count
- TERN 5
- SLN 5
- Target Price
- TERN $15.63
- SLN $32.60
- AVG Volume (30 Days)
- TERN 932.0K
- SLN 120.4K
- Earning Date
- TERN 08-04-2025
- SLN 08-14-2025
- Dividend Yield
- TERN N/A
- SLN N/A
- EPS Growth
- TERN N/A
- SLN N/A
- EPS
- TERN N/A
- SLN N/A
- Revenue
- TERN N/A
- SLN $27,701,000.00
- Revenue This Year
- TERN N/A
- SLN N/A
- Revenue Next Year
- TERN N/A
- SLN N/A
- P/E Ratio
- TERN N/A
- SLN N/A
- Revenue Growth
- TERN N/A
- SLN N/A
- 52 Week Low
- TERN $1.87
- SLN $1.97
- 52 Week High
- TERN $11.40
- SLN $22.47
- Technical
- Relative Strength Index (RSI)
- TERN 61.74
- SLN 58.20
- Support Level
- TERN $3.66
- SLN $5.06
- Resistance Level
- TERN $4.30
- SLN $6.25
- Average True Range (ATR)
- TERN 0.31
- SLN 0.48
- MACD
- TERN -0.01
- SLN -0.03
- Stochastic Oscillator
- TERN 59.28
- SLN 63.20
About TERN Terns Pharmaceuticals Inc.
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases. Its product candidates include TERN-701, TERN-601, TERN-501 and TERN-800.
About SLN Silence Therapeutics Plc American Depository Share
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.